- Details
- In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased...
|
- Details
- In a conversation with Andrea Miyahira, Eugene Shenderov discusses the recent study conducted by his team and published under the title, “Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase II Trial.” In the past, immunotherapies have demonstrated limited efficacy in prostate cancer treatment. This is primarily due to the necessity for selective immunotherapy in this settin...
|
- Details
- Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...
|
- Details
- Matthew Cooperberg and Daniel Lin discuss the update to the American Urological Association's (AUA) prostate cancer screening guideline in this discussion. They highlight the collaborative effort involved in the guideline update, involving a large group of experts and reviewers. They compare the AUA's process with that of the National Comprehensive Cancer Network (NCCN) and discuss the systematic...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- Alicia Morgans and Oliver Sartor discuss the New England Journal of Medicine editorial on the fifteen-year follow-up of the ProtecT trial. The ProtecT trial was a UK-based study where 1600 men were randomized to either active monitoring, prostatectomy, or radiotherapy. The trial followed up on these men for 15 years and found that there were no significant differences in mortality between the grou...
|
- Details
- In this conversation, Alicia Morgans speaks with Professor David Penson about the ProtecT trial and its implications for clinical practice. The study found no difference in outcomes between surgery, radiation, and conservative management in prostate cancer patients after 10 years of follow-up. However, a recent 15-year follow-up has revealed some new findings. The cohort of patients enrolled in th...
|
- Details
- Zachary Klaassen is joined by Neil Mariados, the lead author on both the SpaceOAR™ and Barrigel® trials to discuss rectal spacing, which is used in radiation therapy to reduce rectal toxicity in prostate cancer patients. Rectal spacing involves inserting a gel between the rectum and the prostate to create a space that reduces the dose to the rectum during radiation. They compare the two FDA-approv...
|
- Details
- Matt Cooperberg interviews Tyler Seibert, a radiation oncologist and assistant professor at UC San Diego. They focus on the use of MRI for localized prostate cancer, which has drastically changed the diagnostic pathway for prostate cancer in the last decade. However, the variability in the way the MRI is conducted is a problem. Each imaging center sets up its own protocol, and this lack of coordin...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the Urologic Oncology publication entitled Out-of-pocket costs for commercially insured patients with localized prostate cancer. Financial burdens may contribute to long-term effects on patient's health-related quality of life. However, costs are rarely included in shared decision-making conversations, and most studies available have focus...
|
